Results 21 to 30 of about 1,506 (115)

Cerebrospinal Fluid Concentration of the RET Inhibitor Pralsetinib: A Case Report

Case Reports in Oncology, 2023
Introduction: Pralsetinib is used to treat metastatic RET fusion-positive non-small cell lung cancer. Preclinical studies of pralsetinib have shown blood-brain barrier (BBB) penetration and intracranial activity.
Loek A.W. De Jong, Rolf W. Sparidans, Michel M. van den Heuvel   +2 more
doaj   +1 more source

Pralsetinib treatment for multiple fusions in lung adenocarcinoma: a case report

Journal of International Medical Research, 2022
Despite recent advances in treatments and knowledge of biomarkers, patients with metastatic lung cancer have a 5-year survival rate of 5%. Rearranged during transfection ( RET ) fusions occur in 1% to 2% of lung cancer patients. Pralsetinib has been used
Xiangming Cao, Xiongwei Liu, Simin Wang, Zhen Liu, Xin Ren, Debin Sun, Lichun Deng   +6 more
doaj   +1 more source

Case report: Recurrent lung infections following treatment with pralsetinib for an elderly patient with RET-fusion positive NSCLC

Frontiers in Oncology, 2022
Patients with RET fusions represent 1-2% of all cases of non-small cell lung cancer (NSCLC), the majority of whom are younger, and are extremely rare in the elderly.
Li An, Pengzhi Chen, Junfeng Wang, Xuebing Qin, Tingting Liu, Yanhong Gao, Peng Wang, Dong Zhang, Xiangqun Fang, Zhijian Zhang   +9 more
doaj   +1 more source

Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient

Frontiers in Oncology, 2022
The identification of receptor-tyrosine kinase gene (RET) fusions in lung cancer has become crucial owing to actionable events that predict responsiveness to tyrosine kinase inhibitors (TKIs).
Sha-Sha Wang, Fang Wang, Zhen Zeng, Fang Gao, Huan-Huan Liu, Hui-Na Wang, Yi Hu, Hai-Feng Qin   +7 more
doaj   +1 more source

ESMO Updates the Guidelines for the Diagnosis of *RET*-Altered Cancer to Herald a New Era in Targeted Therapy

healthbook TIMES. Oncology Hematology, 2021
The *RET* gene encodes a tyrosine kinase receptor that regulates cell survival and proliferation by triggering key downstream pathways.^1^ *RET* gene mutations and *RET* gene fusions are involved in the pathogenesis of lung, thyroid and other cancers ...
Alfredo Addeo, Frank Stenner
doaj   +2 more sources

Response to Pralsetinib Observed in Meningeal-Metastatic EGFR-Mutant NSCLC With Acquired RET Fusion: A Brief Report

JTO Clinical and Research Reports, 2022
Introduction: RET is well known as an important driver gene in NSCLC. Moreover, RET is a rare acquired resistance mechanism to EGFR-mutant NSCLC. Only 36 NSCLC cases of coexistence of EGFR and RET were reported previously worldwide.
Zichen Zhao, MD, Chao Su, PhD, Weigang Xiu, MD, Weiya Wang, MD, Shasha Zeng, MD, Meijuan Huang, MD, Youling Gong, MD, You Lu, MD, PhD, Yan Zhang, MD, PhD   +8 more
doaj   +1 more source

RET rearrangement-positive pancreatic cancer has remarkable response to pralsetinib: a case report

Frontiers in Oncology, 2023
Patients with metastatic pancreatic cancer have limited treatment options and a dismal prognosis. While RET fusion is rare (0.6%) in pancreatic cancer, the efficacy of RET-targeted treatment in patients with TRIM33-RET fusion has not been previously ...
Tongyi Zhang, Hongwei Wang, Zhiwei Cai, Siqi Zhang, Chongyi Jiang, Chongyi Jiang   +5 more
doaj   +1 more source

Current Guidelines for Management of Medullary Thyroid Carcinoma [PDF]

Endocrinology and Metabolism, 2021
Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor originating from the parafollicular cells. The diagnostic and therapeutic strategies for the condition are different from those used for well-differentiated thyroid cancer.
Mijin Kim, Bo Hyun Kim
doaj   +1 more source

Correction: Review and analysis of clinical trials of selective RET inhibitors for the treatment of thyroid cancer [PDF]

Frontiers in Oncology
Yulu Zhou, Yulu Zhou, Junjie Cao, Siqi Zhang, Mingjun Sun, Yaqi Zhang, Songzhe Li, Zining Luo, Pengyu Wang, Jiebin Xie   +9 more
doaj   +2 more sources

Non-small-cell lung cancer: how to manage RET-positive disease

Drugs in Context, 2022
Targeted therapy has dramatically changed the history and outcomes of oncogene-addicted non-small-cell lung cancer (NSCLC). RET rearrangements are typically observed in about 1–2% of NSCLC, resulting in constitutive activation of downstream signalling ...
Elisa Andrini, Mirta Mosca, Linda Galvani, Francesca Sperandi, Biagio Ricciuti, Giulio Metro, Giuseppe Lamberti   +6 more
doaj   +1 more source